The future of integrase inhibitors of HIV-1

Current Opinion in Virology

Volumn 2, Issue 5, 2012, Pages 580-587

  Malet, Isabelle ^a   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MK 2048; MK 2058; PLACEBO; RALTEGRAVIR; RITONAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84867402822     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.08.005     Document Type: Review

References (50)

1. R. Craigie, and F.D. Bushman HIV DNA integration Cold Spring Harbor Perspectives in Medicine 2 2012 a006890
2. M.C. Shun, N.K. Raghavendra, N. Vandegraaff, J.E. Daigle, S. Hughes, P. Kellam, P. Cherepanov, and A. Engelman LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration Genes and Development 21 2007 1767 1778
3. A. Ciuffi, M. Llano, E. Poeschla, C. Hoffmann, J. Leipzig, P. Shinn, J.R. Ecker, and F. Bushman A role for LEDGF/p75 in targeting HIV DNA integration Nature Medicine 11 2005 1287 1289
4. M.K. Lewinski, M. Yamashita, M. Emerman, A. Ciuffi, H. Marshall, G. Crawford, F. Collins, P. Shinn, J. Leipzig, and S. Hannenhalli Retroviral DNA integration: viral and cellular determinants of target-site selection PLoS Pathogens 2 2006 e60
5. A. Engelman, and R. Craigie Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro Journal of Virology 66 1992 6361 6369
6. S. Hare, A.M. Vos, R.F. Clayton, J.W. Thuring, M.D. Cummings, and P. Cherepanov Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance Proceedings of the National Academy of Sciences of the United States of America 107 2010 20057 20062
7. J. Kulkosky, K.S. Jones, R.A. Katz, J.P. Mack, and A.M. Skalka Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases Molecular and Cellular Biology 12 1992 2331 2338
8. A. Faure, C. Calmels, C. Desjobert, M. Castroviejo, A. Caumont-Sarcos, L. Tarrago-Litvak, S. Litvak, and V. Parissi HIV-1 integrase crosslinked oligomers are active in vitro Nucleic Acids Research 33 2005 977 986
9. E. Guiot, K. Carayon, O. Delelis, F. Simon, P. Tauc, E. Zubin, M. Gottikh, J.F. Mouscadet, J.C. Brochon, and E. Deprez Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity Journal of Biological Chemistry 281 2006 22707 22719
10. D.J. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J.A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, and C. Blau Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 287 2000 646 650
11. S. Bera, K.K. Pandey, A.C. Vora, and D.P. Grandgenett Molecular interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration Journal of Molecular Biology 389 2009 183 198
12. T. Kawasuji, M. Fuji, T. Yoshinaga, A. Sato, T. Fujiwara, and R. Kiyama A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors Bioorganic and Medicinal Chemistry 14 2006 8420 8429
13. C. Marchand, A.A. Johnson, R.G. Karki, G.C. Pais, X. Zhang, K. Cowansage, T.A. Patel, M.C. Nicklaus, T.R. Burke Jr., and Y. Pommier Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S) Molecular Pharmacology 64 2003 600 609
14. J.L. Blanco, V. Varghese, S.Y. Rhee, J.M. Gatell, and R.W. Shafer HIV-1 integrase inhibitor resistance and its clinical implications Journal of Infectious Diseases 203 2011 1204 1214
15. B. Grinsztejn, B.Y. Nguyen, C. Katlama, J.M. Gatell, A. Lazzarin, D. Vittecoq, C.J. Gonzalez, J. Chen, C.M. Harvey, and R.D. Isaacs Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial Lancet 369 2007 1261 1269
16. V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O. Gonzalez Paz, and D.J. Hazuda Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection Journal of Medicinal Chemistry 51 2008 5843 5855
17. J.L. Lennox, E. DeJesus, A. Lazzarin, R.B. Pollard, J.V. Madruga, D.S. Berger, J. Zhao, X. Xu, A. Williams-Diaz, and A.J. Rodgers Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
18. M. Markowitz, B.Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J.O. Morales-Ramirez, C.S. Crumpacker, and R.D. Isaacs Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study Journal of Acquired Immune Deficiency Syndromes 46 2007 125 133
19. R.T. Steigbigel, D.A. Cooper, P.N. Kumar, J.E. Eron, M. Schechter, M. Markowitz, M.R. Loutfy, J.L. Lennox, J.M. Gatell, and J.K. Rockstroh Raltegravir with optimized background therapy for resistant HIV-1 infection New England Journal of Medicine 359 2008 339 354
20. R.T. Steigbigel, D.A. Cooper, H. Teppler, J.J. Eron, J.M. Gatell, P.N. Kumar, J.K. Rockstroh, M. Schechter, C. Katlama, and M. Markowitz Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials Clinical Infectious Diseases 50 2010 605 612
21. J.J. Eron, B. Young, D.A. Cooper, M. Youle, E. Dejesus, J. Andrade-Villanueva, C. Workman, R. Zajdenverg, G. Fatkenheuer, and D.S. Berger Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials Lancet 375 2010 396 407
22. M. Sato, T. Motomura, H. Aramaki, T. Matsuda, M. Yamashita, Y. Ito, H. Kawakami, Y. Matsuzaki, W. Watanabe, and K. Yamataka Novel HIV-1 integrase inhibitors derived from quinolone antibiotics Journal of Medicinal Chemistry 49 2006 1506 1508
23. T. Wills, and V. Vega Elvitegravir: a once-daily inhibitor of HIV-1 integrase Expert Opinion on Investigational Drugs 21 2012 395 401
24. E. DeJesus, J. Rockstroh, K. Henry, J.M. Molina, J. Gathe, S. Ramanathan, X. Wei, J. Szwarcberg, A. Jandourek, and A. Cheng Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects showing efficacy, safety, and pharmacokinetics 19th Conference on Retroviruses and Opportunistic Infections Seattle 2012
25. P. Sax, E. DeJesus, A. Mills, A. Zolopa, C. Cohen, D. Wohl, J. Gallant, H. Liu, E. Quirk, and B. Kearney Elvitegravir/cobicistat/emtricitabine/tenofovir (quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects 19th Conference on Retroviruses and Opportunistic Infections Seattle, March 5-8 2012
26. S. Min, I. Song, J. Borland, S. Chen, Y. Lou, T. Fujiwara, and S.C. Piscitelli Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers Antimicrobial Agents and Chemotherapy 54 2010 254 258
27. J. van Lunzen, F. Maggiolo, J.R. Arribas, A. Rakhmanova, P. Yeni, B. Young, J.K. Rockstroh, S. Almond, I. Song, and C. Brothers Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial Lancet Infectious Diseases 12 2012 111 118
28. V. Soriano, J. Cox, J.J. Eron, P.N. Kumar, C. Katlama, A. Lazzarin, I. Poizot-Martin, G. Richmond, M. Ait-Khaled, and T. Fujiwara Dolutegravir (DTG, S/GSK1349572) treatment of HIV suppression at week 24 in the VIKING study 13th European AIDS Conference (EACS) Belgrade, Serbia, 12-15 October 2011 2011
29. L.Q. Al-Mawsawi, R.I. Al-Safi, and N. Neamati Anti-infectives: clinical progress of HIV-1 integrase inhibitors Expert Opinion on Emerging Drugs 13 2008 213 225
30. J.P. Vacca, J.S. Wai, T.E. Fisher, M.W. Embrey, D.J. Hazuda, M.D. Miller, P.J. Felock, M.V. Witmer, L.J. Gabryelski, and T.A. Lyle Discovery of MK-2048 - subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors IAS Conference Sydney, Australia 2007
31. P.K. Quashie, R.D. Sloan, and M.A. Wainberg Novel therapeutic strategies targeting HIV integrase BMC Medicine 10 2012 34
32. D.A. Cooper, R.T. Steigbigel, J.M. Gatell, J.K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, P.N. Kumar, and J.E. Eron Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection New England Journal of Medicine 359 2008 355 365
33. I. Malet, O. Delelis, M.A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, and J.F. Mouscadet Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro Antimicrobial Agents and Chemotherapy 52 2008 1351 1358
34. K. Shimura, E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, Y. Watanabe, Y. Ohata, S. Doi, and M. Sato Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) Journal of Virology 82 2008 764 774
35. J.D. Croxtall, and S.J. Keam Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients Drugs 69 2009 1059 1075
36. O. Delelis, S. Thierry, F. Subra, F. Simon, I. Malet, C. Alloui, S. Sayon, V. Calvez, E. Deprez, and A.G. Marcelin Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo Antimicrobial Agents and Chemotherapy 54 2010 491 501
37. N. Sichtig, S. Sierra, R. Kaiser, M. Daumer, S. Reuter, E. Schulter, A. Altmann, G. Fatkenheuer, U. Dittmer, and H. Pfister Evolution of raltegravir resistance during therapy Journal of Antimicrobial Chemotherapy 64 2009 25 32
38. O. Goethals, R. Clayton, M. Van Ginderen, I. Vereycken, E. Wagemans, P. Geluykens, K. Dockx, R. Strijbos, V. Smits, and A. Vos Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors Journal of Virology 82 2008 10366 10374
39. M. Kobayashi, T. Yoshinaga, T. Seki, C. Wakasa-Morimoto, K.W. Brown, R. Ferris, S.A. Foster, R.J. Hazen, S. Miki, and A. Suyama-Kagitani In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor Antimicrobial Agents and Chemotherapy 55 2011 813 821
40. P.K. Quashie, T. Mesplede, Y.S. Han, M. Oliveira, D.N. Singhroy, T. Fujiwara, M.R. Underwood, and M.A. Wainberg Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir Journal of Virology 86 2012 2696 2705
41. T. Bar-Magen, R.D. Sloan, D.A. Donahue, B.D. Kuhl, A. Zabeida, H. Xu, M. Oliveira, D.J. Hazuda, and M.A. Wainberg Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor Journal of Virology 84 2010 9210 9216
42. J.C. Lenz, and J.K. Rockstroh S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges Expert Opinion on Investigational Drugs 20 2011 537 548
43. I. Malet, S. Fourati, C. Charpentier, L. Morand-Joubert, D. Armenia, M. Wirden, S. Sayon, M. Van Houtte, F. Ceccherini-Silberstein, and F. Brun-Vezinet The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02-AG HIV-1 subtype Journal of Antimicrobial Chemotherapy 66 2011 2827 2830
44. N.A. Margot, R.M. Hluhanich, G.S. Jones, K.N. Andreatta, M. Tsiang, D.J. McColl, K.L. White, and M.D. Miller In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4 Antiviral Research 93 2012 288 296
45. E.C. Reuman, M.H. Bachmann, V. Varghese, W.J. Fessel, and R.W. Shafer Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector Antimicrobial Agents and Chemotherapy 54 2010 934 936
46. T. Seki, M. Kobayashi, S. Miki, E. Akihisa, A. Suyama-Kagitani, S. Kawauchi-Miki, T. Yoshinaga, T. Fujiwara, and A. Sato High barrier to resistance for dolutegravir (DTG, S/GSK1349572) against raltegravir-resistant Y143 mutants: an in vitro passage study International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies Sitges, Spain, June 5-9 2012
47. L. Van Wesenbeeck, E. Rondelez, M. Feyaerts, A. Verheyen, K. Van der Borght, V. Smits, C. Cleybergh, H. De Wolf, K. Van Baelen, and L.J. Stuyver Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates Antimicrobial Agents and Chemotherapy 55 2011 321 325
48. F. Christ, A. Voet, A. Marchand, S. Nicolet, B.A. Desimmie, D. Marchand, D. Bardiot, N.J. Van der Veken, B. Van Remoortel, and S.V. Strelkov Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication Nature Chemical Biology 6 2010 442 448
49. F. Christ, S. Shaw, J. Demeulemeester, B.A. Desimmie, A. Marchand, S. Butler, W. Smets, P. Chaltin, M. Westby, and Z. Debyser Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization Antimicrobial Agents and Chemotherapy 56 2012 4365 4374
50. F. Christ, C. Pickford, S. Shaw, J. Demeulemeester, B.A. Desimmie, C. Smith-Burchnell, S. Butler, M. Westby, and Z. Debyser Preclinical evaluation of HIV replication inhibitors that target the HIV integrase-LEDGF/p75 interaction 19th Conference on Retroviruses and Opportunistic Infections Seattle 2012